Literature DB >> 15864305

Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance.

Jeffrey P MacKeigan1, Leon O Murphy, John Blenis.   

Abstract

Evasion from apoptosis is a hallmark of cancer, and recent success using targeted therapeutics underscores the importance of identifying anti-apoptotic survival pathways. Here we utilize RNA interference (RNAi) to systematically screen the kinase and phosphatase component of the human genome. In addition to known kinases, we identified several new survival kinases. Interestingly, numerous phosphatases and associated regulatory subunits contribute to cell survival, revealing a previously unrecognized general role for phosphatases as negative regulators of apoptosis. We also identified a subset of phosphatases with tumour-suppressor-like activity. Finally, RNAi targeting of specific protein kinases sensitizes resistant cells to chemotherapeutic agents. The development of inhibitors that target these kinases or phosphatases may lead to new anti-cancer strategies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15864305     DOI: 10.1038/ncb1258

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  194 in total

1.  An Integrated Genetic-Genomic Approach for the Identification of Novel Cancer Loci in Mice Sensitized to c-Myc-Induced Apoptosis.

Authors:  Susan M Mendrysa; Keiko Akagi; Jean Roayaei; Wen-Hui Lien; Neal G Copeland; Nancy A Jenkins; Robert N Eisenman
Journal:  Genes Cancer       Date:  2010-05

2.  The ups and downs of DNA repair biomarkers for PARP inhibitor therapies.

Authors:  Xiaozhe Wang; David T Weaver
Journal:  Am J Cancer Res       Date:  2010-01-03       Impact factor: 6.166

Review 3.  Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?

Authors:  Tetyana V Bagnyukova; Ilya G Serebriiskii; Yan Zhou; Elizabeth A Hopper-Borge; Erica A Golemis; Igor Astsaturov
Journal:  Cancer Biol Ther       Date:  2010-11-01       Impact factor: 4.742

4.  Expression of ROR1 in patients with renal cancer--a potential diagnostic marker.

Authors:  Hodjattallah Rabbani; Mahyar Ostadkarampour; Amir Hossein Danesh Manesh; Abbas Basiri; Mahmood Jeddi-Tehrani; Flora Forouzesh
Journal:  Iran Biomed J       Date:  2010-07

5.  RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors.

Authors:  S E Martin; Z-H Wu; K Gehlhaus; T L Jones; Y-W Zhang; R Guha; S Miyamoto; Y Pommier; N J Caplen
Journal:  Curr Cancer Drug Targets       Date:  2011-10       Impact factor: 3.428

6.  Aberrant Expression of proPTPRN2 in Cancer Cells Confers Resistance to Apoptosis.

Authors:  Alexey V Sorokin; Binoj C Nair; Yongkun Wei; Kathryn E Aziz; Valentina Evdokimova; Mien-Chie Hung; Junjie Chen
Journal:  Cancer Res       Date:  2015-04-15       Impact factor: 12.701

Review 7.  Is Cdc25 a druggable target?

Authors:  John S Lazo; Peter Wipf
Journal:  Anticancer Agents Med Chem       Date:  2008-12       Impact factor: 2.505

8.  Protein kinase A type II-α regulatory subunit regulates the response of prostate cancer cells to taxane treatment.

Authors:  Evan R Zynda; Vitaliy Matveev; Michael Makhanov; Alexander Chenchik; Eugene S Kandel
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 9.  WNT signalling pathways as therapeutic targets in cancer.

Authors:  Jamie N Anastas; Randall T Moon
Journal:  Nat Rev Cancer       Date:  2013-01       Impact factor: 60.716

10.  Trauma-associated human neutrophil alterations revealed by comparative proteomics profiling.

Authors:  Jian-Ying Zhou; Ravi K Krovvidi; Yuqian Gao; Hong Gao; Brianne O Petritis; Asit K De; Carol L Miller-Graziano; Paul E Bankey; Vladislav A Petyuk; Carrie D Nicora; Therese R Clauss; Ronald J Moore; Tujin Shi; Joseph N Brown; Amit Kaushal; Wenzhong Xiao; Ronald W Davis; Ronald V Maier; Ronald G Tompkins; Wei-Jun Qian; David G Camp; Richard D Smith
Journal:  Proteomics Clin Appl       Date:  2013-05-22       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.